Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer

Abstract

Patients with advanced gastric cancer (AGC) are often treated with irinotecan monotherapy as salvage-line therapy. However, the survival benefit of this therapy remains to be elucidated. Medical records of AGC patients who were treated with irinotecan monotherapy as salvage-line treatment in six institutions from 2007 to 2014 were reviewed. A total of 146… (More)
DOI: 10.1007/s10120-017-0759-9

Topics

6 Figures and Tables

Slides referencing similar topics